Recent Press Releases

Gilead cuts ribbon on innovative new laboratory, announces additional $100m investment in Edmonton

Gilead cuts ribbon on innovative new laboratory, announces additional $100m investment in Edmonton Company's investment totals $200M for facilities that will help develop new drugs EDMONTON, May...

Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)

KENILWORTH, N.J. & SEATTLE--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration...

Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy

NOVATO, Calif., May 28, 2015 -- Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the...

Padlock Therapeutics Accelerates Pipeline Development Through Agreement with GSK

-- Creates Industry-Leading R&D Effort Focused on Creating PAD Inhibitors for the Treatment of Autoimmune Diseases – CAMBRIDGE, Mass. – May 28, 2015 – Padlock Therapeutics, a...

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital

Mapi Pharma Closes $10 Million Investment Led by Shavit Capital NESS ZIONA, Israel, May 27, 2015 / -- Mapi Pharma Ltd. announced today that Shavit Capital has led an investment round of $10 million...

Karolinska Institutet launches new collaborations for innovation and research

Karolinska Institutet launches new collaborations for innovation and research Karolinska Institute's wholly owned company, Karolinska Institutet Holding AB, has signed an agreement with Johnson &...

GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients

LOUISVILLE, CO--GlobeImmune, Inc. (GBIM) today announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term viral suppression with an oral antiviral...

Retrophin Agrees to Sell Priority Review Voucher to Sanofi

SAN DIEGO-- Retrophin, Inc. (NASDAQ:RTRX) today announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher ("Pediatric PRV") to Sanofi (NYSE:SNY). Retrophin received...

bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 26, 2015 -- bluebird bio, Inc. (BLUE) and Five Prime Therapeutics, Inc. (FPRX) today announced that they have entered into an exclusive license...

Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies

Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies Alliance combines Editas' genome editing technology and expertise...

Calimmune Completes $15 Million Series B Financing

Calimmune Completes $15 Million Series B Financing Proceeds Will Advance Clinical Trials for Gene-Based HIV/AIDS Therapies May 27, 2015 08:00 AM Eastern Daylight Time TUCSON, Ariz.--(...

AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today. Consistent with the...

Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 clinical trial with ALN-AS1, a...

NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion® in South Korea

STOCKHOLM--Regulatory News: NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with...

FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD

RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and...

Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment by European Regulators

First Investigational Therapy for Fabry Disease to be Granted Accelerated Assessment Planned MAA Submission on Track for 2Q15 to Request Full Approval in European Union CRANBURY, N.J., May 26,...

Amgen to terminate participation in co-development and commercialization of brodalumab

Amgen to terminate participation in co-development and commercialization of brodalumab THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Company has...

GSK submits Japan regulatory application for mepolizumab in severe eosinophilic asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for mepolizumab as an add-on maintenance...

Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

SEATTLE, May 22, 2015 -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both...

Cellular Biomedicine Group Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program

SHANGHAI, China and PALO ALTO, Calif., May 22, 2015 -- Cellular Biomedicine Group Inc. (CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective...